Ironshore Pharms patents expiration
1. Jornay Pm patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9028868 | IRONSHORE PHARMS | Methods and compositions for treatment of attention deficit disorder |
Mar, 2032
(8 years from now) | |
| US9034902 | IRONSHORE PHARMS | Methods for treatment of attention deficit hyperactivity disorder |
Mar, 2032
(8 years from now) | |
| US8916588 | IRONSHORE PHARMS | Methods for treatment of attention deficit hyperactivity disorder |
Mar, 2032
(8 years from now) | |
| US9603809 | IRONSHORE PHARMS | Methods of treatment of attention deficit hyperactivity disorder |
Mar, 2032
(8 years from now) | |
| US10292937 | IRONSHORE PHARMS | Methods of treatment of attention deficit hyperactivity disorder |
Mar, 2032
(8 years from now) | |
| US10617651 | IRONSHORE PHARMS | Compositions for treatment of attention deficit hyperactivity disorder |
Mar, 2032
(8 years from now) | |
| US10881618 | IRONSHORE PHARMS | Compositions for treatment of attention deficit hyperactivity disorder |
Mar, 2032
(8 years from now) | |
| US11241391 | IRONSHORE PHARMS | Compositions for treatment of attention deficit hyperactivity disorder |
Mar, 2032
(8 years from now) | |
| US11241392 | IRONSHORE PHARMS | Compositions for treatment of attention deficit hyperactivity disorder |
Mar, 2032
(8 years from now) | |
| US9498447 | IRONSHORE PHARMS | Compositions for treatment of attention deficit hyperactivity disorder |
Mar, 2032
(8 years from now) | |
| US9283214 | IRONSHORE PHARMS | Compositions for treatment of attention deficit hyperactivity disorder |
Mar, 2032
(8 years from now) | |
| US9023389 | IRONSHORE PHARMS | Compositions for treatment of attention deficit hyperactivity disorder |
Mar, 2032
(8 years from now) | |
| US8927010 | IRONSHORE PHARMS | Compositions for treatment of attention deficit hyperactivity disorder |
Mar, 2032
(8 years from now) | |
| US10182995 | IRONSHORE PHARMS | Compositions for treatment of attention deficit hyperactivity disorder |
Mar, 2032
(8 years from now) | |
| US10905652 | IRONSHORE PHARMS | Compositions for treatment of attention deficit hyperactivity disorder |
Mar, 2032
(8 years from now) | |
Drugs and Companies using METHYLPHENIDATE HYDROCHLORIDE ingredient
Market Authorisation Date: 08 August, 2018
Treatment: Method of treating attention deficit hyperactivity disorder (adhd)
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
More Information on Dosage
JORNAY PM family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic